Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

A Merck drug developed to prevent disease from respiratory syncytial virus (RSV) in infants has won FDA ... vaccine comprised of an engineered version of RSV F protein antigen. It was first ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...

CHARLOTTE — The Food and Drug Administration approved a new vaccine to help protect infants from RSV on Monday. The treatment ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants ... their mothers did not receive a maternal RSV vaccine.

Merck said in a release that it expects orders for the shot to begin in July, with shipments delivered before the virus starts to spread widely. The approval gives doctors a new option for ...